Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Eric Davis

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Nature|January 2, 2009
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survivalNicolas Bidère, Vu N Ngo, Jeansun Lee, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Blood|February 10, 2019
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myelomaJunling Zhuang, Fazal Shirazi, Ram Kumar Singh, et al.
Leukemia|June 15, 2021
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AMLYuki Nishida, Ran Zhao, Lauren E Heese, et al.
Blood|June 25, 2017
Tonic B-cell receptor signaling in diffuse large B-cell lymphomaOndrej Havranek, Jingda Xu, Stefan Köhrer, et al.
Blood|March 7, 2014
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistanceRodrigo Jacamo, Ye Chen, Zhiqiang Wang, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Nature|January 2, 2009
Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survivalNicolas Bidère, Vu N Ngo, Jeansun Lee, et al.
Blood|August 31, 2012
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myelomaDeborah J Kuhn, Zuzana Berkova, Richard J Jones, et al.
Blood|February 10, 2019
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myelomaJunling Zhuang, Fazal Shirazi, Ram Kumar Singh, et al.
Leukemia|June 15, 2021
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AMLYuki Nishida, Ran Zhao, Lauren E Heese, et al.
Blood|June 25, 2017
Tonic B-cell receptor signaling in diffuse large B-cell lymphomaOndrej Havranek, Jingda Xu, Stefan Köhrer, et al.
Blood|March 7, 2014
Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistanceRodrigo Jacamo, Ye Chen, Zhiqiang Wang, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Pageof 9